Zacks Research Has Bullish Forecast for Stryker Q1 Earnings

Stryker Co. (NYSE:SYK) – Equities researchers at Zacks Research increased their Q1 2025 earnings estimates for shares of Stryker in a report issued on Monday, November 18th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical technology company will post earnings of $2.82 per share for the quarter, up from their previous forecast of $2.74. The consensus estimate for Stryker’s current full-year earnings is $12.06 per share. Zacks Research also issued estimates for Stryker’s Q3 2025 earnings at $3.26 EPS, Q4 2025 earnings at $4.23 EPS and FY2025 earnings at $13.53 EPS.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business had revenue of $5.49 billion for the quarter, compared to analysts’ expectations of $5.37 billion. During the same period in the prior year, the firm earned $2.46 EPS. The company’s revenue for the quarter was up 11.9% on a year-over-year basis.

Other equities analysts also recently issued research reports about the company. BTIG Research boosted their target price on Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Robert W. Baird increased their price objective on shares of Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Canaccord Genuity Group boosted their target price on Stryker from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Truist Financial boosted their target price on shares of Stryker from $370.00 to $380.00 and gave the company a “hold” rating in a research note on Wednesday, October 30th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Stryker from $375.00 to $420.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, Stryker presently has an average rating of “Moderate Buy” and an average price target of $393.65.

Stryker Stock Up 1.1 %

Shares of NYSE:SYK opened at $389.88 on Thursday. The company has a market cap of $148.63 billion, a price-to-earnings ratio of 41.79, a PEG ratio of 2.93 and a beta of 0.91. Stryker has a 12 month low of $285.79 and a 12 month high of $398.20. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The company has a 50-day moving average price of $365.91 and a 200 day moving average price of $348.95.

Hedge Funds Weigh In On Stryker

Several hedge funds and other institutional investors have recently made changes to their positions in SYK. Wealth Enhancement Advisory Services LLC raised its holdings in Stryker by 78.9% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 133,020 shares of the medical technology company’s stock valued at $45,260,000 after acquiring an additional 58,673 shares during the last quarter. OFI Invest Asset Management raised its stake in Stryker by 3,210.9% during the second quarter. OFI Invest Asset Management now owns 3,344 shares of the medical technology company’s stock worth $1,062,000 after purchasing an additional 3,243 shares during the period. Tidal Investments LLC boosted its holdings in Stryker by 14.2% in the 1st quarter. Tidal Investments LLC now owns 13,558 shares of the medical technology company’s stock valued at $4,853,000 after purchasing an additional 1,681 shares during the last quarter. Envestnet Asset Management Inc. increased its holdings in shares of Stryker by 2.7% during the 2nd quarter. Envestnet Asset Management Inc. now owns 618,041 shares of the medical technology company’s stock worth $210,289,000 after buying an additional 16,504 shares during the last quarter. Finally, Sivik Global Healthcare LLC increased its holdings in shares of Stryker by 8.0% during the 3rd quarter. Sivik Global Healthcare LLC now owns 27,000 shares of the medical technology company’s stock worth $9,754,000 after buying an additional 2,000 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Transactions at Stryker

In other news, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. This trade represents a 36.43 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Viju Menon sold 600 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the sale, the insider now directly owns 9,069 shares of the company’s stock, valued at $3,219,495. This represents a 6.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 67,381 shares of company stock worth $24,825,275 over the last quarter. 5.90% of the stock is currently owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.